Repligen Corporation (RGEN) is a public company. Repligen, a global, bioprocessing-focused life sciences company, provides innovative solutions for the advancement of biotherapeutic manufacturing. Experts in filtration, chromatography systems, process analytics, fluid management, and proteins, Repligen is a trusted partner serving the development and manufacture of a wide range of biologics, including cell and gene therapies, mRNA, monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), bispecific antibodies, and fusion proteins. Headquartered in Waltham, Massachusetts, USA, Repligen operates across 22 sites, including locations in the United States, Europe, and the Asia-Pacific region. Founded in 1981. It has 1,496 employees. Annual revenue is $738.3M. IPO 1986.

Transcript

Operator

Hello everyone. Thank you for joining us, and welcome to the Repligen Q2 2026 earnings call. After today's prepared remarks, we will host a question-and-answer session. If you'd like to ask a question, please press star one to raise your hand. To withdraw your question, please press star one again. I would now like to turn the call over to your host for today's call, Jacob Johnson, Vice President of Investor Relations for Repligen.

Jacob Johnson — VP of Investor Relations

Thank you, operator. Welcome everyone to our 2026 second quarter report. On this call, we will cover business highlights and financial performance for the three-month period ending June 30th, 2026, and will provide financial guidance for the full year 2026. Joining us on the call today are Repligen's President and Chief Executive Officer, Olivier Loeillot, and our Chief Financial Officer, Jason Garland. As a reminder, the forward-looking statements that we make during this call, including those regarding our business goals and expectations for the financial performance of the company, are subject to risks and uncertainties that may cause actual events or results to differ. Additional information concerning risks related to our business is included in our quarterly reports on Form 10-Q, our annual report on Form 10-K, and our current reports, including the Form 8-K that we are filing today, and other filings that we make with the Securities and Exchange Commission. Today's comments reflect management's current views, which could change as a result of new information, future events, or otherwise. The company does not oblige or commit